Heron Therapeutics (HRTX) Short Interest Ratio & Short Volume $1.92 -0.01 (-0.52%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.88 -0.04 (-2.34%) As of 05:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Heron Therapeutics Short Interest DataHeron Therapeutics (HRTX) has a short interest of 32.52 million shares, representing 22.69% of the float (the number of shares available for trading by the public). This marks a 1.40% increase in short interest from the previous month. The short interest ratio (days to cover) is 18.8, indicating that it would take 18.8 days of the average trading volume of 2.35 million shares to cover all short positions.Current Short Interest32,520,000 sharesPrevious Short Interest32,070,000 sharesChange Vs. Previous Month+1.40%Dollar Volume Sold Short$71.54 millionShort Interest Ratio18.8 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares152,330,000 sharesShort Percent of Float22.69%Today's Trading Volume696,140 sharesAverage Trading Volume2,353,925 sharesToday's Volume Vs. Average30% Short Selling Heron Therapeutics? Sign up to receive the latest short interest report for Heron Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartHRTX Short Interest Over TimeHRTX Days to Cover Over TimeHRTX Percentage of Float Shorted Over Time Remove Ads Heron Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202532,520,000 shares $71.54 million +1.4%22.7%18.8 $2.20 3/15/202532,070,000 shares $74.40 million +2.4%22.4%17.5 $2.32 2/28/202531,330,000 shares $77.39 million +1.8%21.9%10.2 $2.47 2/15/202530,770,000 shares $54.77 million -0.2%21.5%10.7 $1.78 1/31/202530,840,000 shares $52.43 million -0.7%N/A10 $1.70 1/15/202531,060,000 shares $47.21 million +1.1%N/A10 $1.52 12/31/202430,710,000 shares $46.99 million +2.4%N/A9.9 $1.53 12/15/202429,980,000 shares $47.97 million +8.9%N/A9.6 $1.60 11/30/202427,540,000 shares $32.77 million -1.3%N/A8.8 $1.19 11/15/202427,910,000 shares $33.21 million -3.1%N/A15.3 $1.19 Get the Latest News and Ratings for HRTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/31/202428,810,000 shares $50.13 million -6.0%N/A15.7 $1.74 10/15/202430,640,000 shares $55.15 million -3.3%N/A14.9 $1.80 9/30/202431,700,000 shares $63.08 million -10.6%N/A14.4 $1.99 9/15/202435,440,000 shares $66.27 million -1.3%N/A14.9 $1.87 8/31/202435,920,000 shares $69.33 million -0.1%N/A15.5 $1.93 8/15/202435,960,000 shares $70.12 million +0.9%N/A14.9 $1.95 7/31/202435,630,000 shares $105.82 million -0.1%N/A14.9 $2.97 7/15/202435,660,000 shares $118.03 million +8.7%N/A14.7 $3.31 6/30/202432,820,000 shares $114.87 million +7.7%N/A14 $3.50 6/15/202430,470,000 shares $109.69 million +1.4%N/A14.5 $3.60 5/31/202430,040,000 shares $111.15 million -0.8%N/A12.3 $3.70 5/15/202430,270,000 shares $90.81 million +10.9%N/A12.6 $3.00 4/30/202427,290,000 shares $63.31 million +7.3%N/A11.6 $2.32 4/15/202425,430,000 shares $75.02 million -0.5%N/A9.8 $2.95 3/31/202425,550,000 shares $70.77 million +0.5%N/A8.8 $2.77 3/15/202425,430,000 shares $77.82 million +3.7%N/A8.4 $3.06 2/29/202424,530,000 shares $65.25 million -0.4%N/A8.8 $2.66 2/15/202424,620,000 shares $70.91 million +1.2%N/A8.4 $2.88 1/31/202424,330,000 shares $58.64 million +13.1%N/A6.6 $2.41 1/15/202421,520,000 shares $46.27 million +6.5%N/A6.5 $2.15 12/31/202320,210,000 shares $34.36 million -3.8%N/A6 $1.70 12/15/202321,000,000 shares $38.01 million -2.7%N/A6.8 $1.81 11/30/202321,580,000 shares $26.54 million +22.7%N/A7.4 $1.23 11/15/202317,590,000 shares $15.13 million -4.5%N/A6.4 $0.86 10/31/202318,410,000 shares $11.73 million -4.9%N/A9.1 $0.64 10/15/202319,360,000 shares $13.99 million -26.5%N/A8.9 $0.72 9/30/202326,330,000 shares $27.12 million +2.3%N/A12.8 $1.03 9/15/202325,750,000 shares $31.16 million +1.7%N/A13.4 $1.21 8/31/202325,320,000 shares $41.52 million -8.8%N/A12.7 $1.64 8/15/202327,760,000 shares $46.50 million +14.2%N/A13.2 $1.68Trump’s treachery (Ad)Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma 7/31/202324,310,000 shares $40.35 million +9.4%N/A10.4 $1.66 7/15/202322,220,000 shares $28.22 million -1.0%N/A10.1 $1.27 6/30/202322,440,000 shares $26.03 million -2.0%N/A9.7 $1.16 6/15/202322,890,000 shares $29.99 million -2.1%N/A8.9 $1.31 5/31/202323,380,000 shares $26.65 million +8.0%N/A9 $1.14 5/15/202321,650,000 shares $28.79 million -2.9%N/A8.8 $1.33 4/30/202322,300,000 shares $53.30 million -3.8%N/A10.8 $2.39 4/15/202323,190,000 shares $63.31 million +0.2%N/A10.8 $2.73 3/31/202323,150,000 shares $34.96 million +1.5%N/A10.9 $1.51 3/15/202322,800,000 shares $53.81 million -2.0%N/A12.7 $2.36 2/28/202323,270,000 shares $55.15 million -11.0%N/A10.2 $2.37 2/15/202326,140,000 shares $68.75 million -2.4%N/A11.2 $2.63 1/31/202326,790,000 shares $72.60 million -1.0%N/A10.5 $2.71 1/15/202327,070,000 shares $85.81 million +8.2%N/A10.7 $3.17 12/30/202225,030,000 shares $62.58 million -13.2%N/A9.7 $2.50 12/15/202228,840,000 shares $73.25 million +2.2%N/A10.8 $2.54 11/30/202228,220,000 shares $76.48 million -0.6%N/A10 $2.71 11/15/202228,400,000 shares $90.88 million -1.3%N/A10.1 $3.20 10/31/202228,770,000 shares $110.76 million -1.4%N/A9.3 $3.85 10/15/202229,180,000 shares $107.09 million -12.7%N/A9 $3.67 9/30/202233,420,000 shares $141.03 million +2.1%N/A10.1 $4.22 9/15/202232,720,000 shares $159.35 million +0.2%N/A9.7 $4.87 8/31/202232,650,000 shares $133.54 million -4.0%N/A10.8 $4.09 8/15/202234,000,000 shares $182.58 million -15.9%N/A11.2 $5.37 7/31/202240,430,000 shares $112.40 million +0.6%N/A14.3 $2.78 7/15/202240,180,000 shares $118.13 million +10.3%N/A14.9 $2.94 6/30/202236,440,000 shares $101.67 million -6.5%47.0%13.8 $2.79 6/15/202238,980,000 shares $99.40 million +5.5%50.3%15.5 $2.55 5/31/202236,960,000 shares $121.97 million -0.1%N/A14.6 $3.30 5/15/202236,980,000 shares $132.76 million -0.1%N/A14.4 $3.59 4/30/202237,010,000 shares $167.29 million -0.5%N/A15.7 $4.52 4/15/202237,200,000 shares $218.36 million -5.3%N/A16.2 $5.87 3/31/202239,280,000 shares $224.68 million +16.0%N/A17.1 $5.72 3/15/202233,850,000 shares $163.83 million -2.6%N/A15 $4.84 2/28/202234,750,000 shares $246.73 million -1.4%N/A15.2 $7.10 2/15/202235,240,000 shares $311.52 million +1.7%N/A16.9 $8.84 1/31/202234,640,000 shares $301.71 million -6.3%N/A16.5 $8.71 1/15/202236,960,000 shares $321.55 million +0.9%N/A0 $8.70 12/31/202136,650,000 shares $334.61 million +7.9%N/A18.9 $9.13 12/15/202133,970,000 shares $306.41 million +8.1%N/A17.6 $9.02 11/30/202131,430,000 shares $297.01 million +2.1%N/A18.8 $9.45 11/15/202130,790,000 shares $336.53 million +3.6%N/A21.4 $10.93 10/29/202129,730,000 shares $327.33 million +5.2%N/A21.4 $11.01 10/15/202128,270,000 shares $299.38 million +5.1%N/A21.4 $10.59 9/30/202126,900,000 shares $287.56 million +2.0%N/A20.2 $10.69 9/15/202126,370,000 shares $307.47 million -3.1%N/A21.3 $11.66 8/31/202127,220,000 shares $317.66 million +5.9%N/A21.3 $11.67 8/13/202125,710,000 shares $284.10 million +0.1%N/A17.3 $11.05 7/30/202125,690,000 shares $317.53 million +5.9%N/A14 $12.36 7/15/202124,250,000 shares $317.43 million +2.2%N/A13.9 $13.09Trump’s treachery (Ad)Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma 6/30/202123,720,000 shares $368.13 million -1.4%N/A13.8 $15.52 6/15/202124,050,000 shares $372.05 million +1.6%N/A14.5 $15.47 5/28/202123,680,000 shares $314.23 million +11.8%N/A14.5 $13.27 5/14/202121,180,000 shares $329.03 million +0.8%N/A14.3 $15.54 4/30/202121,010,000 shares $370.20 million -1.9%N/A20.4 $17.62 4/15/202121,410,000 shares $369.75 million +1.5%N/A21.2 $17.27 3/31/202121,100,000 shares $322.83 million +2.7%N/A20.9 $15.30 3/15/202120,550,000 shares $348.12 million +2.0%N/A19 $16.94 2/26/202120,150,000 shares $363.71 million +2.2%N/A19.4 $18.05 2/12/202119,710,000 shares $364.83 million +3.0%N/A19.1 $18.51 1/29/202119,140,000 shares $351.41 million +7.8%N/A17.9 $18.36 1/15/202117,760,000 shares $325.72 million +1.3%N/A17.2 $18.34 12/31/202017,530,000 shares $372.86 million -0.4%N/A18.8 $21.27 12/15/202017,600,000 shares $316.10 million -5.2%N/A19.8 $17.96 11/30/202018,560,000 shares $333.89 million +2.5%N/A23 $17.99 11/15/202018,100,000 shares $328.15 million +3.6%N/A23.2 $18.13 10/30/202017,480,000 shares $280.38 million +0.5%N/A24.2 $16.04 10/15/202017,390,000 shares $272.85 million +2.0%N/A23.5 $15.69 9/30/202017,050,000 shares $252.68 million +10.5%N/A20.4 $14.82 9/15/202015,430,000 shares $238.86 million +0.8%N/A12.2 $15.48 8/31/202015,310,000 shares $218.93 million -6.0%N/A11.6 $14.30 8/14/202016,280,000 shares $252.50 million +1.5%N/A12.2 $15.51 7/31/202016,040,000 shares $261.29 million -5.3%N/A11.5 $16.29 7/15/202016,930,000 shares $277.65 million -9.9%N/A11.8 $16.40 6/30/202018,790,000 shares $276.40 million +10.2%N/A13.4 $14.71 6/15/202017,050,000 shares $326.68 million +2.6%N/A15.8 $19.16 5/29/202016,620,000 shares $306.14 million -0.2%N/A13.5 $18.42 5/15/202016,650,000 shares $251.75 million -2.8%N/A12.7 $15.12 4/30/202017,120,000 shares $244.13 million +3.2%N/A13 $14.26 HRTX Short Interest - Frequently Asked Questions What is Heron Therapeutics' current short interest? Short interest is the volume of Heron Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, traders have sold 32,520,000 shares of HRTX short. 22.69% of Heron Therapeutics' shares are currently sold short. Learn More on Heron Therapeutics' current short interest. What is a good short interest ratio for Heron Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. HRTX shares currently have a short interest ratio of 19.0. Learn More on Heron Therapeutics's short interest ratio. Which institutional investors are shorting Heron Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Heron Therapeutics: Wolverine Trading LLC, Group One Trading LLC, Citadel Advisors LLC, Susquehanna International Group LLP, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Heron Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 22.69% of Heron Therapeutics' floating shares are currently sold short. Is Heron Therapeutics' short interest increasing or decreasing? Heron Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 32,520,000 shares, an increase of 1.4% from the previous total of 32,070,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Heron Therapeutics' short interest compare to its competitors? 22.69% of Heron Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Heron Therapeutics: Amphastar Pharmaceuticals, Inc. (9.72%), Adaptive Biotechnologies Co. (7.31%), Ardelyx, Inc. (13.75%), Evotec SE (0.24%), Aurinia Pharmaceuticals Inc. (9.41%), Ocular Therapeutix, Inc. (8.30%), Iovance Biotherapeutics, Inc. (28.32%), Syndax Pharmaceuticals, Inc. (23.65%), Wave Life Sciences Ltd. (9.19%), Collegium Pharmaceutical, Inc. (14.66%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Heron Therapeutics stock? Short selling HRTX is an investing strategy that aims to generate trading profit from Heron Therapeutics as its price is falling. HRTX shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Heron Therapeutics? A short squeeze for Heron Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of HRTX, which in turn drives the price of the stock up even further. How often is Heron Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HRTX, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies Amphastar Pharmaceuticals Short Squeeze Adaptive Biotechnologies Short Squeeze Ardelyx Short Squeeze Evotec Short Squeeze Aurinia Pharmaceuticals Short Squeeze Ocular Therapeutix Short Squeeze Iovance Biotherapeutics Short Squeeze Syndax Pharmaceuticals Short Squeeze Wave Life Sciences Short Squeeze Collegium Pharmaceutical Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:HRTX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMusk's panic move: What the world's richest man fears is comingWhether you have modest savings of $10,000 or substantial wealth of $10 million, this information could determ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.